Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

ACTIVE NOT RECRUITING

Identifier: CI-TRIAL-00112408
Entity page: /trial/NCT02632708 ↗
Edges: 10

Neighbours: 2 cancers7 drugs
Drawn: 9 of 9 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation condition of …CONDITION_OFderived3 of 3
← condition of	Acute Myeloid Leukemia registry condition “Newly Diagnosed Acute Myeloid Leukemia (AML)” mapped CURATED_BROADER	—	—	Acute Myeloid Leukemia	1	Observed	clinicaltrials	graph →
← condition of	Acute Myeloid Leukemia registry condition “Untreated AML” mapped CURATED_BROADER

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation intervention of …INTERVENTION_OFderived7 of 7
← intervention of	Cytarabinesmall molecule registry intervention “cytarabine” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Daunorubicinsmall molecule registry intervention “daunorubicin” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Enasidenibsmall molecule registry intervention “AG-221” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Etoposidesmall molecule registry intervention “etoposide” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Idarubicinsmall molecule registry intervention “idarubicin” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Ivosidenibsmall molecule registry intervention “AG-120” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Mitoxantronesmall molecule registry intervention “mitoxantrone” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation intervention of …INTERVENTION_OFderived7 of 7

← intervention of

Cytarabinesmall molecule

registry intervention “cytarabine” (DRUG) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →

← intervention of

Daunorubicinsmall molecule

registry intervention “daunorubicin” (DRUG) mapped ALIAS

—